Printable Datasheet

Recombinant CD16 / FcγReceptor III Antibody [FCGR3A/12961R]

In Stock
Catalog Number Formulation Size Price
2214-RBM9-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$259.00
2214-RBM9-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$559.00
2214-RBM9-P1ABX
Purified Ab WITHOUT BSA or Azide at 1.0mg/ml
100ug
$559.00
Flat Rate Domestic: $95 | Orders outside the US - Contact Us for Order Information | Ships next business day
CD16 / FCGR3A Antibody in Western Blot (WB)

CD16 / FCGR3A Antibody in Western Blot (WB)

Western Blot Analysis of Human Spleen and Rat Spleen tissue lysates using CD16 / FCGR3A Recombinant Rabbit Monoclonal Antibody (FCGR3A/12961R).

CD16 / FCGR3A Antibody in Western Blot (WB)

CD16 / FCGR3A Antibody in Western Blot (WB)

Western Blot Analysis of Human Lung, Mouse Lung and Rat Lung tissue lysates using CD16 / FCGR3A Recombinant Rabbit Monoclonal Antibody (FCGR3A/12961R).

CD16 / FCGR3A Antibody in Western Blot (WB)

CD16 / FCGR3A Antibody in Western Blot (WB)

Western Blot Analysis of Human Spleen, Mouse Spleen, Rat Spleen, Hamster Spleen, Guinea pig Spleen, Human Lungs, Mouse Lungs, Rat Lungs, Hamster Lungs and Guinea pig Lungs tissue lysates using CD16 / FCGR3A Recombinant Rabbit Monoclonal Antibody (FCGR3A/12961R).

CD16 Antibody in SDS-PAGE

CD16 Antibody in SDS-PAGE

SDS-PAGE Analysis of Purified CD16 Recombinant Rabbit Monoclonal Antibody (FCGR3A/12961R). Confirmation of Purity and Integrity of Antibody.

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
IHC Protocol
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes
Western Blot (WB)
2-4ug/ml
Western Blot Protocol

Summary

It recognizes CD16 (FcgammaRIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80kDa. Two similar genes represent CD16, CD16A (FcgammaRIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (FcgammaRIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation.

Product Properties & Targets

Antibody Type
Recombinant Mouse Monoclonals
Host
Rabbit
Applications
Immunohistochemistry, Western Blot
Species Reactivity
Human
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Cell membrane, Secreted
Gene Name
FCGR3A
Positive Control
K-562 or U-937 cells. Human Spleen, Human Lung, Lymph nodes and tonsils.
Immunogen
Recombinant fragment (around aa1-254) of the human CD16 protein (exact sequence is proprietary)
Alternate Names
Low affinity immunoglobulin gamma Fc region receptor III-A, CD16|CD16-II|CD16A|FCG3|FCGR3|FCGRIII|FCR-10|FCRIII|FCRIIIA|FcGRIIIA|IGFR3|IMD20

Database Links

Entrez Gene ID
2214
SwissProt
P08637

Additional Information

Clone
FCGR3A/12961R
Chromosome Location
1q23.3
Mol. Weight of Antigen
29.09kDa
Expression System
CHO Cells
Purification
Protein A

Related Antibodies

View All FCGR3A Antibodies

Functions

  • Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed:11711607, PubMed:21768335, PubMed:22023369, PubMed:24412922, PubMed:25786175, PubMed:25816339, PubMed:28652325, PubMed:8609432, PubMed:9242542). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed:24412922, PubMed:25786175). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed:29967280, PubMed:9916693). Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed:1825220, PubMed:23024279, PubMed:2532305). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed:10318937, PubMed:23006327). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed:27670158). Mediates enhanced ADCC in response to afucosylated IgGs (PubMed:34485821)., (Microbial infection) Involved in Dengue virus pathogenesis via antibody-dependent enhancement (ADE) mechanism. Secondary infection with Dengue virus triggers elevated levels of afucosylated non-neutralizing IgG1s with reactivity to viral envelope/E protein. Viral antigen-IgG1 complexes bind with high affinity to FCGR3A, facilitating virus entry in myeloid cells and subsequent viral replication.

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab produced in a mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK
Call Us Now: 1-866-2-NEOBIO (1-866-263-6246)
NeoBiotechnologies Logo
Company Info
Antibodies
Antibody Validation
Research Areas
Resources
Newsletter Signup Updates & Sales